📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Tetraphase Pharmaceuticals

1.1 - Company Overview

Tetraphase Pharmaceuticals Logo

Tetraphase Pharmaceuticals

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of therapeutics for significant disease categories, including GIAPREZA to increase blood pressure in adults with septic or other distributive shock; XERAVA for complicated intra-abdominal infections in adults; XACDURO for hospital- and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex; and investigational zoliflodacin for uncomplicated gonorrhea.

Products and services

  • XACDURO (sulbactam for injection
  • Durlobactam for injection): Delivers an antibacterial combination for injection approved to treat adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex strains
  • XERAVA (eravacycline): Offers an adult-indicated eravacycline antibiotic for the treatment of complicated intra-abdominal infections in adults, in adult patients
  • GIAPREZA (angiotensin II): Produces an approved drug to increase blood pressure in adults with septic or other distributive shock

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Tetraphase Pharmaceuticals

Sunshine Biopharma Logo

Sunshine Biopharma

HQ: United States Website
  • Description: Provider of research, development, and commercialization of drugs for the treatment of various forms of cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sunshine Biopharma company profile →
Biocure Technology Logo

Biocure Technology

HQ: Canada Website
  • Description: Provider of biosimilars and CAR-T cell pharmaceutical products.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Biocure Technology company profile →
PhagoMed Logo

PhagoMed

HQ: Austria Website
  • Description: Provider of a biotech platform for developing drugs and therapies, focusing on human therapeutic applications of phages and phage-derived proteins to address urinary tract infections and bacterial vaginosis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PhagoMed company profile →
Bacterial Barcodes Logo

Bacterial Barcodes

HQ: United States Website
  • Description: Provider of equipment, reagents, and software for microbial genotyping of bacteria and fungi, packaged as the DiversiLab System, serving the clinical diagnostic market for bacterial identification.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bacterial Barcodes company profile →
Okairos Logo

Okairos

HQ: Switzerland Website
  • Description: Provider of biopharmaceutical discovery and development of genetic T-cell vaccines, including for hepatitis C virus, and health and allied services. Based in Basel, Switzerland, with operations in Rome and Naples, Italy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Okairos company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Tetraphase Pharmaceuticals

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Tetraphase Pharmaceuticals

2.2 - Growth funds investing in similar companies to Tetraphase Pharmaceuticals

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Tetraphase Pharmaceuticals

4.2 - Public trading comparable groups for Tetraphase Pharmaceuticals

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Tetraphase Pharmaceuticals

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Tetraphase Pharmaceuticals

What does Tetraphase Pharmaceuticals do?

Tetraphase Pharmaceuticals is a provider of therapeutics for significant disease categories, including GIAPREZA to increase blood pressure in adults with septic or other distributive shock; XERAVA for complicated intra-abdominal infections in adults; XACDURO for hospital- and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex; and investigational zoliflodacin for uncomplicated gonorrhea.

Who are Tetraphase Pharmaceuticals's competitors?

Tetraphase Pharmaceuticals's competitors and similar companies include Sunshine Biopharma, Biocure Technology, PhagoMed, Bacterial Barcodes, and Okairos.

Where is Tetraphase Pharmaceuticals headquartered?

Tetraphase Pharmaceuticals is headquartered in United States.

How many employees does Tetraphase Pharmaceuticals have?

Tetraphase Pharmaceuticals has 1,000 employees 🔒.

When was Tetraphase Pharmaceuticals founded?

Tetraphase Pharmaceuticals was founded in 2010 🔒.

What sector and industry vertical is Tetraphase Pharmaceuticals in?

Tetraphase Pharmaceuticals is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Tetraphase Pharmaceuticals

Who are the top strategic acquirers in Tetraphase Pharmaceuticals's sector and industry

Top strategic M&A buyers and acquirers in Tetraphase Pharmaceuticals's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Tetraphase Pharmaceuticals?

Top strategic M&A buyers groups and sectors for Tetraphase Pharmaceuticals include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Tetraphase Pharmaceuticals's sector and industry vertical

Which are the top PE firms investing in Tetraphase Pharmaceuticals's sector and industry vertical?

Top PE firms investing in Tetraphase Pharmaceuticals's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Tetraphase Pharmaceuticals's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Tetraphase Pharmaceuticals's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Tetraphase Pharmaceuticals's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Tetraphase Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Tetraphase Pharmaceuticals's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Tetraphase Pharmaceuticals?

The key public trading comparables and valuation benchmarks for Tetraphase Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Tetraphase Pharmaceuticals for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Tetraphase Pharmaceuticals with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Tetraphase Pharmaceuticals's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Tetraphase Pharmaceuticals with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Tetraphase Pharmaceuticals's' sector and industry vertical?

Access recent funding rounds and capital raises in Tetraphase Pharmaceuticals's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Tetraphase Pharmaceuticals